Skip to main content
. Author manuscript; available in PMC: 2024 Feb 6.
Published in final edited form as: Circ Genom Precis Med. 2023 Feb 22;16(2):e003726. doi: 10.1161/CIRCGEN.122.003726

Figure 5 |. The novel ALG10B-p.G6S variant is necessary for action potential prolongation in the patient’s iPSC-CMs.

Figure 5 |

A. Representative patch-clamp AP traces from isogenic control (black) and ALG10B-G6S-derived iPSC-CMs (red) paced at 1Hz. B. Representative patch-clamp AP traces from isogenic control (black) and ALG10B-G6S-derived iPSC-CMs (red) in gap free configuration. C. Bar graph showing APD50 from isogenic control (n= 13) and ALG10B-G6S (n=15) iPSC-CMs paced at 1 Hz. D. Bar graph showing APD90 from isogenic control (n= 13) and ALG10B-G6S (n=15) iPSC-CMs paced at 1 Hz. E. Representative multielectrode assay (MEA) plus local extracellular action potential (LEAP) based stable beatings (on top) and APD (on bottom) traces of isogenic control (left panel) and ALG10B-G6S (right panel)-derived iPSC-CMs. F. Bar graph showing APD30, APD50, APD90 and corrected APD90 (APD90c) from isogenic control (n=76 electrodes in 12 wells and ALG10B-G6S (n=88 electrodes in 12 wells). All values in panel C, D, and F represent mean±SEM.